Compare Stocks: ELYM, TYRA, TRAX, and DMRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMRA Damora Therapeutics, Inc. Common Stock	$20.65 +2.1%	$27.42	$3.64 ▼ $38.33	$1.27B	1.43	794,600 shs	692,888 shs
ELYM Eliem Therapeutics	$10.94 -1.2%	$14.16	$2.35 ▼ $11.55	$325.49M	-0.39	486,688 shs	1.58 million shs
TRAX First Tracks Biotherapeutics	$33.28 -1.9%	$41.52	$14.72 ▼ $49.91	$1.19B	N/A	672,269 shs	1.17 million shs
TYRA Tyra Biosciences	$20.43 -2.8%	$25.84	$12.98 ▼ $40.65	$1.22B	0.75	1.46 million shs	1.05 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMRA Damora Therapeutics, Inc. Common Stock	0.00%	-0.05%	-26.25%	-31.12%	+486.65%
ELYM Eliem Therapeutics	-1.17%	-6.17%	-27.31%	-15.19%	+444.28%
TRAX First Tracks Biotherapeutics	0.00%	-3.31%	-21.71%	+72.44%	+3,327,999,900.00%
TYRA Tyra Biosciences	0.00%	-6.11%	-17.82%	-33.28%	+52.24%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMRA Damora Therapeutics, Inc. Common Stock	$20.65 +2.1%	$27.42	$3.64 ▼ $38.33	$1.27B	1.43	794,600 shs	692,888 shs
ELYM Eliem Therapeutics	$10.94 -1.2%	$14.16	$2.35 ▼ $11.55	$325.49M	-0.39	486,688 shs	1.58 million shs
TRAX First Tracks Biotherapeutics	$33.28 -1.9%	$41.52	$14.72 ▼ $49.91	$1.19B	N/A	672,269 shs	1.17 million shs
TYRA Tyra Biosciences	$20.43 -2.8%	$25.84	$12.98 ▼ $40.65	$1.22B	0.75	1.46 million shs	1.05 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMRA Damora Therapeutics, Inc. Common Stock	0.00%	-0.05%	-26.25%	-31.12%	+486.65%
ELYM Eliem Therapeutics	-1.17%	-6.17%	-27.31%	-15.19%	+444.28%
TRAX First Tracks Biotherapeutics	0.00%	-3.31%	-21.71%	+72.44%	+3,327,999,900.00%
TYRA Tyra Biosciences	0.00%	-6.11%	-17.82%	-33.28%	+52.24%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DMRA Damora Therapeutics, Inc. Common Stock	3.00	Buy	$46.50	125.18% Upside
ELYM Eliem Therapeutics	0.00	N/A	N/A	N/A
TRAX First Tracks Biotherapeutics	2.79	Moderate Buy	$65.17	95.81% Upside
TYRA Tyra Biosciences	2.86	Moderate Buy	$46.89	129.51% Upside

Current Analyst Ratings Breakdown

Latest ELYM, TYRA, TRAX, and DMRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	TRAX First Tracks Biotherapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00
9/29/2026	DMRA Damora Therapeutics, Inc. Common Stock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
9/25/2026	DMRA Damora Therapeutics, Inc. Common Stock	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $60.00
9/23/2026	TYRA Tyra Biosciences	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/22/2026	TYRA Tyra Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$50.00 ➝ $40.00
9/22/2026	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$30.00 ➝ $29.00
9/18/2026	TRAX First Tracks Biotherapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
9/18/2026	TRAX First Tracks Biotherapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
9/16/2026	TRAX First Tracks Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$100.00
9/16/2026	TRAX First Tracks Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
9/16/2026	TRAX First Tracks Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$100.00

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	($110.11) per share	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	$3.90 per share	N/A
TRAX First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$4.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DMRA Damora Therapeutics, Inc. Common Stock	-$209.84M	-$3.37	N/A	N/A	N/A	N/A	-176.39%	-77.86%	N/A
ELYM Eliem Therapeutics	-$35.12M	-$0.53	N/A	N/A	N/A	N/A	-47.03%	-45.97%	N/A
TRAX First Tracks Biotherapeutics	N/A	-$1.84	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	-$119.95M	-$2.40	N/A	N/A	N/A	N/A	-46.39%	-43.07%	11/4/2026 (Estimated)

Latest ELYM, TYRA, TRAX, and DMRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	TRAX First Tracks Biotherapeutics	-$0.74	-$0.95	-$0.21	-$0.95	N/A	N/A
8/10/2026	Q2 2026	DMRA Damora Therapeutics, Inc. Common Stock	-$0.4470	-$0.39	+$0.0570	-$0.39	N/A	N/A
8/4/2026	Q2 2026	TYRA Tyra Biosciences	-$0.6499	-$0.69	-$0.0401	-$0.69	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A
TRAX First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DMRA Damora Therapeutics, Inc. Common Stock	N/A	19.73	19.73
ELYM Eliem Therapeutics	N/A	60.41	60.41
TRAX First Tracks Biotherapeutics	N/A	14.28	14.28
TYRA Tyra Biosciences	N/A	14.90	14.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DMRA Damora Therapeutics, Inc. Common Stock	14.20%
ELYM Eliem Therapeutics	69.76%
TRAX First Tracks Biotherapeutics	N/A
TYRA Tyra Biosciences	84.14%

Insider Ownership

Company	Insider Ownership
DMRA Damora Therapeutics, Inc. Common Stock	0.40%
ELYM Eliem Therapeutics	4.70%
TRAX First Tracks Biotherapeutics	N/A
TYRA Tyra Biosciences	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DMRA Damora Therapeutics, Inc. Common Stock	40	61.74 million	61.49 million	No Data
ELYM Eliem Therapeutics	9	29.75 million	28.35 million	Not Optionable
TRAX First Tracks Biotherapeutics	104	35.73 million	N/A	N/A
TYRA Tyra Biosciences	87	59.68 million	52.22 million	Optionable

ELYM, TYRA, TRAX, and DMRA Headlines

Recent News About These Companies

Raymond James Updates Healthcare Top Picks for October

October 3 at 7:25 AM | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

October 1 at 10:00 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

September 29, 2026 | globenewswire.com

Bank of America Corp DE Purchases 349,732 Shares of Tyra Biosciences, Inc. $TYRA

September 26, 2026 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Price Target of $46.89

September 25, 2026 | americanbankingnews.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Target Price of $46.89

September 25, 2026 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Shares Down 6.7% After Analyst Downgrade

September 25, 2026 | americanbankingnews.com

Equities Analysts Set Expectations for TYRA FY2026 Earnings

September 24, 2026 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Trading Down 6.7% on Analyst Downgrade

September 23, 2026 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Price Target Lowered to $29.00 at HC Wainwright

September 22, 2026 | marketbeat.com

RA Capital Management Acquires Over 9 Million Derivative Securities in Tyra Biosciences (NASDAQ: TYRA)

September 20, 2026 | kalkinemedia.comK

Fuhrman Alan Acquires Additional 951 Shares, Holding 37,115 Tyra Biosciences Stocks Post-Award

September 20, 2026 | kalkinemedia.comK

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

September 17, 2026 | prnewswire.com

Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?

September 16, 2026 | insidermonkey.com

Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets

September 16, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

September 15, 2026 | globenewswire.com

Squarepoint Ops LLC Purchases 43,311 Shares of Tyra Biosciences, Inc. $TYRA

September 15, 2026 | marketbeat.com

Tyra Bioscience Shares Rise After Pricing $400 Million Offering

September 14, 2026 | marketscreener.comM

Tyra Biosciences Shares Rise After $400 Million Offering Prices

September 14, 2026 | marketwatch.com

Biotech Stocks On The Move: Tyra, Nasus, Bionano & Tenaya Make Gains

September 14, 2026 | rttnews.com

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up - Time to Buy?

September 14, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM, TYRA, TRAX, and DMRA Company Descriptions

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

$20.65 +0.42 (+2.08%)

As of 10/2/2026 04:00 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Eliem Therapeutics NASDAQ:ELYM

$10.94 -0.13 (-1.17%)

As of 10/2/2026

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

First Tracks Biotherapeutics NASDAQ:TRAX

$33.28 -0.64 (-1.89%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$33.31 +0.03 (+0.09%)

As of 10/2/2026 07:30 PM Eastern

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

Tyra Biosciences NASDAQ:TYRA

$20.43 -0.58 (-2.76%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$20.42 -0.01 (-0.05%)

As of 10/2/2026 07:30 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELYM, TYRA, TRAX, and DMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELYM, TYRA, TRAX, and DMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELYM, TYRA, TRAX, and DMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM, TYRA, TRAX, and DMRA Company Descriptions

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Eliem Therapeutics NASDAQ:ELYM

First Tracks Biotherapeutics NASDAQ:TRAX

Tyra Biosciences NASDAQ:TYRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELYM, TYRA, TRAX, and DMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELYM, TYRA, TRAX, and DMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELYM, TYRA, TRAX, and DMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM, TYRA, TRAX, and DMRA Company Descriptions

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Eliem Therapeutics NASDAQ:ELYM

First Tracks Biotherapeutics NASDAQ:TRAX

Tyra Biosciences NASDAQ:TYRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools